<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871882</url>
  </required_header>
  <id_info>
    <org_study_id>15-007765</org_study_id>
    <nct_id>NCT02871882</nct_id>
  </id_info>
  <brief_title>Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus</brief_title>
  <official_title>Effect of Delayed-Release Bile Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Satiogen Pharmaceuticals, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of an ileocolonic formulation of ox bile extract on insulin sensitivity,
      postprandial glycemia and incretin levels, gastric emptying, body weight and fasting serum
      FGF-19 (fibroblast growth factor) levels in overweight or obese type 2 diabetic subjects on
      therapy with DPP4 (dipeptidyl peptidase-4) inhibitors (e.g. sitagliptin) alone or in
      combination with metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, placebo-controlled, parallel-group, single dose, randomized,
      controlled trial. Participants will receive 28 days (+/- 4 days) of treatment to study the
      effect of delayed (ileocolonic)-release ox bile extract 500 mg BID (twice daily) on insulin
      sensitivity, gastric emptying of liquids and solids (measured by scintigraphy) and weight
      loss I overweight and obese type 2 diabetic subjects. Participants will be receiving therapy
      with DPP4 inhibitors alone or in combination with metformin. Blood samples will be collected
      at defined times to measure glycemia, FGF-19 and incretins (GLP-1 [glucagon-like peptide-1],
      OXM [oxyntomodulin], PYY 3-36 [peptide YY]) fasting levels and responses to the meal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2016</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">October 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>baseline to 1 month</time_frame>
    <description>the conjugated bile acid sodium extract in delayed (ileocolonic)-release formulation, stimulates enteroendocrine L cell secretion in the ileum and colon, increasing the secretion of FGF-19, GLP-1, oxyntomodulin (OXM), and PYY 3-36, and improves insulin sensitivity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Obese</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Ox bile extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ox bile extract 500 mg tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gastric Emptying test</intervention_name>
    <description>participants eat a standardized meal labeled with radioactive markers (99mTc DTPA [diethylenetriaminepentaacetic acid] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.</description>
    <arm_group_label>Ox bile extract</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mixed Oral Glucose Tolerance test</intervention_name>
    <description>Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.</description>
    <arm_group_label>Ox bile extract</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conjugated bile acids sodium</intervention_name>
    <description>500 mg tablets taken orally twice daily for 28 (+/- 4) days</description>
    <arm_group_label>Ox bile extract</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Ox Bile extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets taken orally twice daily for 28 (+/- 4) days</description>
    <arm_group_label>Ox bile extract</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Overweight or obese subjects with BMI &gt; 30 kg/m2 with type 2 diabetes mellitus taking
             DPP4 inhibitors alone or in combination with metformin.

          2. Women of childbearing potential will have a negative pregnancy test before initiation
             of medication and within 48 hours of receiving radioisotope.

        Exclusion criteria:

          1. Structural of metabolic diseases/conditions that affect the gastrointestinal system,
             or functional gastrointestinal disorders.

          2. Irritable bowel syndrome

          3. Bristol stool type classification 4-7 per Bowel Disease questionnaire.

          4. Subjects with other treatment for type 2 diabetes mellitus.

          5. Subjects with HbA1c &gt; 8%

          6. Females who are pregnant or breastfeeding

          7. Concomitant use of appetite suppressants, orlistat, phentermine-topiramate ER or
             lorcaserin.

          8. Subjects who are not currently on treatment for cardiac, pulmonary, gastrointestinal,
             hepatic, renal, hematological, neurological, endocrine (other than type 2 diabetes
             mellitus), and unstable psychiatric disease.

          9. Subjects who have donated blood or plasma in the past 8 weeks.

         10. Subjects who have participated in another study within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Acosta Cardenas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Andres J. Acosta, M.D., Ph.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Acids and Salts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

